This finding is consistent with Han et al., who demonstrated that regorafenib significantly mitigated lipopolysaccharide (LPS)-induced secretion of IL-1β and TNF-α in a mouse model of Alzheimer's disease, suggesting a regulatory effect on the inflammatory response [11]. Here, TNF is linked to Alzheimer disease.